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ABSTRACT 
To evaluate the contribution of association studies of candidate polymorphisms to inherited 
predisposition to Hodgkin lymphoma (HL), we conducted a systematic review and meta-
analysis of published case-control studies. Of the variants examined more than once in 
candidate gene association studies, we identiﬁed 21 studies that reported on 12 
polymorphic variants in 10 genes. Data were also extracted from a published genome 
wide-association study to allow analysis of an additional 47 variants in a further 30 genes. 
Promising associations were seen in nine of the variants (p < 0.05). Given that the 
estimated false positive report probabilities (FPRPs) for all associations are high (i.e. 
FPRP > 0.2), these ﬁndings should be interpreted with caution. While studies of candidate 
polymorphisms may be an attractive means of identifying risk factors for HL, future studies 
should employs ample sizes adequately powered to identify variants having only modest 
effects on HL risk. Furthermore, because of aetiological heterogeneity within HL, 
stratiﬁcation of genotyping according to age, tumour Epstein-Barr virus status and 
histology is essential.  
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INTRODUCTION 
Hodgkin Lymphoma (HL) is a B-cell malignancy affecting ~3 per 100,000 of the population 
each year in most Western countries(1).  HL is typically classified based on 
histopathological appearances into classical HL (cHL) which accounts for 95% of cases 
and nodular lymphocyte predominant HL (NLPHL).  The presence of EBV latent 
membrane protein and/or EBV-encoded small RNAs (EBERs) in Hodgkin Reed-Sternberg 
cells (HRS) defines EBV-positive disease(2).  
Hodgkin lymphoma shows a bimodal age distribution in incidence, with geographic specific 
differences.  In economically developed countries, the first peak of incidence typically 
occurs around 20 years of age with a second peak around 65 years of age(1).  Evidence 
for the existence of inherited genetic predisposition to HL is derived from the high 
concordance rates in identical twins(3) and from case-control studies and cohort studies 
which have shown a 3-fold increased risk of HL in relatives of HL patients(4).   
The failure to identify a major disease-causing locus has led to the proposal that a 
significant component of the inherited susceptibility is enshrined in the co-inheritance of 
multiple risk alleles, some of which are likely to be common.  The most frequent method 
for identifying prevalent low risk variants is through association studies based on 
comparing the frequency of polymorphic genotypes in cases and controls. Alleles 
positively associated with the disease are analogous to risk factors in epidemiology and 
may be causally related to disease risk or be in linkage disequilibrium (LD) with disease-
causing variants. There are a number of different methods of analysing the risk associated 
with a specific variant. For simple bi-allelic polymorphisms, the odds ratio (OR) of disease 
can be derived by comparing allele frequencies in cases and controls. Alternatively, a 
comparison of frequencies of the three genotypes among cases and controls can be 
made, using homozygosity of the “wild-type allele” as the reference group. Where 
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homozygotes are rare, heterozygotes and homozygotes are grouped together, but this is 
only appropriate if a dominant model of disease susceptibility can be assumed. Similarly, 
combining heterozygotes with wild-type homozygotes is only appropriate if alleles act 
recessively. 
The genetic candidates that have been evaluated as susceptibility genes for HL to date 
can be divided into the following groups: immune function/response, carcinogen 
metabolism enzymes, folate metabolism enzymes, DNA repair proteins, and others (table 
1). We elected to exclude candidate gene association studies exploring the human 
leucocyte antigen (HLA) region and HL given the already established predisposition at the 
HLA region(5) and the complex LD structure making identification of the disease-causing 
variant problematic. 
Although some polymorphic variants have only been examined once, most have been 
evaluated as risk factors in several studies but often with discordant findings.  
Furthermore, many of the studies have been based on small sample sizes with limited 
power to robustly demonstrate a relationship with HL risk. To gain better insight into the 
impact of polymorphic variants on risk of HL, we have undertaken a systematic review of 
published studies and used standard meta-analysis techniques according to Cochrane(6) 
In addition, we have used genotype data from a published Genome-Wide Association 
Study (GWAS) to perform a meta-analysis on variants that have only been examined once 
in the literature (7, 8). 
 
 
 
 
Sud et al 
5 
 
 
METHODS 
 
Study identification 
A literature search for studies reporting on the association between polymorphic variants 
and HL was conducted using the electronic database PubMed from May 1991 - December 
2014. The search strategy included using the keywords ‘Hodgkin Lymphoma’, ‘case’, 
‘control’, ‘polymorphism’, ‘risk’, ‘genetic, association’. We searched for additional studies in 
the bibliographies of identified publications, including previous review articles and meta-
analyses(9, 10). 
 
Selection criteria 
Studies were eligible if they were based on unrelated individuals and examined the 
association between HL and variants in candidate genes chosen based on a priori 
knowledge of HL/cancer biology. Variants were only carried forward for meta-analysis if full 
genotype data for both cases and controls were extractable from the article.  Only studies 
published as full-length articles or letters in peer-reviewed journals in English were 
included in the analysis.  
 
Data extraction  
Data for analyses, including study design, sample size and ethnicity as well as allele and 
genotype frequencies, were extracted from the published articles and summarised in a 
consistent manner to aid comparison. 
Sud et al 
6 
 
 
Data extraction from Genome Wide Association Studies 
Where possible, genotype data from 1,465 cases and 6,417 controls were extracted from 
published GWAS to allow the inclusion of variants examined once in the literature (7, 8).   
 
Statistical analysis 
Raw data for genotype frequencies, without adjustment, were used for calculation of the 
study-specific estimates of odds ratio and 95% confidence limits (CIs). Cochran’s Q-
statistic was used to test for heterogeneity, and the percentage variability of the pooled OR 
attributable to heterogeneity between studies was quantified using the I2 statistic (large 
heterogeneity typically defined by I2>75%). A p-value>0.05 for the Q test was considered 
to indicate a lack of heterogeneity across studies, so the pooled estimation of the OR of 
each study was calculated by the fixed-effects model (11). Otherwise, the random effects 
model was employed(12).  The significance of the pooled OR was determined by the Z-
test and p<0.05 was considered as statistically significant.  An estimate of the potential 
publication bias was conducted by the examination of funnel plots, in which the standard 
error (SE) of log(OR) of each study was plotted against its log(OR). An asymmetric plot is 
reflective of publication bias. The funnel plot symmetry was assessed by Egger’s test 
based on inverse-variance weighted regression of the effect sizes on their precision (the 
inverse of standard error), to test whether the intercept deviated significantly from zero; a 
p<0.05 was considered indicative of statistically significant publication bias(13).  To test for 
population stratification (i.e. deviation from Hardy-Weinberg equilibrium (HWE), the 
distribution of genotypes in control subjects of each individual population was tested for 
departure by means of the χ2 test(14).  For each statistically significant association 
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identified, we estimated the false positive reporting probability (FPRP) (15). The FPRP 
value is determined by the p-value, the prior probability for the association, and statistical 
power. We calculated FPRP assuming a prior probability of 0.001 proposed for candidate 
gene analyses(16). Statistical power was based on the ability to detect an OR of 1.2 and 
1.5 (or reciprocal), with α equal to the observed p-value. To evaluate whether the 
association was noteworthy, we imposed a FPRP cut-off value of 0.2, advocated for 
summary analyses. Hence, FPRP values < 0.2 were considered to indicate robust 
associations (15).   
Statistical analyses were undertaken using Stata version 10.0 (Stata Corporation, College 
Station, TX). 
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RESULTS 
Characteristics of published studies  
Meta-analysis of variants studies more than once in the literature 
We retrieved 84 published studies using our search criteria (Figure 1). Of variants 
examined more than once in the literature we identified a total of 21 publications detailing 
12 variants in 10 genes (Table 1).  Six of the variants were genotyped in the published 
GWAS.  All of the published the studies were essentially of similar design, although 
different types of controls have been analysed (Table 2). In the final group, six studies 
included data on ethnicity of cases and controls (17-21), three studies included data on 
EBV-status (17, 22, 23), and eight studies included data on histopathological subtype of 
HL (17, 19, 20, 22, 24-27). Two studies stratified genotype by histology (23, 25), and two 
studies stratified genotypes by EBV-status (22, 23).  ORs of HL associated with each 
polymorphism in individual studies are detailed in the Table 3. 
 
Immune response genes 
One of the two studies which examined the association between IL-10 rs1800890 and HL 
demonstrated a lower risk of HL for those >40 years with homozygosity or carrier status of 
the T allele (24).  The departure of genotype frequencies from HWE (pHWE = 0.02) in the 
control group however suggests population stratification in this study.  Pooling data from 
the both studies failed to demonstrate a significant association between the variant and HL 
risk (Table 4) (24, 28).  In addition, there was no evidence of an association when pooling 
together three studies IL10, rs1800896 nor with the inclusion of data from the GWAS 
(Table 4) (7, 8, 24, 25, 29).   
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Two studies have evaluated rs1800795, a SNP located upstream of IL-6 (21, 23).  One 
study utilised monozygotic and dizygotic twins with at least one affected twin.  When all 
cases were analysed, homozygosity of the C allele appeared to be protective for HL and 
this was identified in the NS subgroup (21).  These findings were not however, supported 
by a larger analysis of unrelated patients with HL nor in the pooled analysis (23) (Table 4). 
 
Carcinogen metabolism genes 
Four studies have investigated the SNP rs1696 in GSTP1 and risk of developing HL (18, 
24, 30, 31).  One study found a protective effect of the heterozygous (AG) genotype (24); 
while another study found the wild type genotype (AA) was associated with an increased 
risk of HL (18) and a third study found the less prevalent genotype (GG) to be associated 
with an increased risk of HL (30) (Table 3).  Two studies demonstrated evidence of 
population stratification with departure from HWE in the controls (pHWE = 0.01).  No 
evidence of association was found when these studies were pooled nor with the inclusion 
of data from the GWAS (Table 4). 
 
Six studies have investigated deletion of the GSTT1 gene and predisposition to HL.  
GSTT1 deletion conferred an increased risk of HL in three studies (24, 27, 32) and no 
effect in three studies (18, 30, 31) (Table 3).  Pooling data from the six studies revealed no 
evidence of association of GSTT1 deletion with HL risk (Table 4). 
Seven studies have examined GSTM1 deletion and risk of developing HL (18, 24, 26, 30-
33).  Neither the studies nor a pooled analysis provides evidence for an association 
between GSTM1 deletion and HL risk (Table 3, Table 4). 
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DNA repair genes 
Two studies have examined the risk of HL and the SNP rs17655 in XPG/ERCC5 (19, 34), 
neither demonstrating an association between genotype and HL risk (Table 3).  However, 
in a pooled analysis, a significant association between XPG/ERCC5, rs17655 CC 
homozygosity and an increased risk of developing HL with an OR=2.03 (95% CI:1.01 - 
4.06, p=0.046) (Figure 2). Furthermore with the addition of data from GWAS the 
association appeared promising 1.68 (95% CI:1.18 – 2.37, p=0.01) (Figure 2 and Table 4).  
There was no evidence of small study effect (Figure 3). 
 
Folate metabolism genes 
Four studies have evaluated the risk of HL with rs1801133, in MTHFR (17, 35-37).  In 
isolation, none of the studies provided evidence for an association between the genotype 
and risk (Table 3).  However, in a pooled analysis, heterozygosity conferred an OR of 0.74 
(95% CI:0.578 - 0.95, p=0.018) and carrier status an OR of 0.75 (95% CI: 0.60 - 0.96, 
p=0.019).  However, with the addition of GWAS data no association was demonstrated 
(Table 4). 
Two studies have evaluated the risk of HL with rs1805087 in MTR (17, 34).  Neither 
demonstrated an association (Table 3). Similarly no association was shown in a meta-
analysis which included GWAS data (Table 4).   
 
Other Genes 
Three studies have investigated the role of rs20417 in COX2 and HL risk (20, 22, 38).  
One study demonstrated an association with both carrier and homozygous minor genotype 
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(20) (Table 3).  However in a pooled analysis with the inclusion of data from GWAS no 
association was seen (Table 4).  Two studies have also examined the risk of HL rs689466 
in COX2, but no association is seen (Table 4) (22, 38).     
Finally, two studies have investigated the tandem repeat in UGT1A1 and HL risk.  No 
significant association was seen in either study (Table 3).  A pooled analysis did not 
provide evidence for a relationship between UGT1A1 genotype and HL (Table 4) (24, 31). 
 
Variants examined once in published studies 
Using directly typed SNPs from the GWAS, we were able to include an additional 47 
variants published in eight papers (39-46).  There was evidence for association in eight of 
these variants (p<0.05). 
 
False Positive Report Probability 
To evaluate the robustness of the three significant findings from the pooled analyses, we 
calculated FPRP conditional on a prior probability of 0.001. None of the above results are 
not considered noteworthy on the basis of the pre-defined assumptions (Table 4 and Table 
5). For example, although the summary OR from the pooled analysis of rs17655 indicated 
a statistically significant positive association with risk, the FPRP was 0.99 which is much 
higher than the conventionally accepted threshold cut off for noteworthiness of <0.2. 
  
Sud et al 
12 
 
DISCUSSION 
 
It is clear that substantial research has been carried out examining polymorphic variants in 
a number of putative candidate genes as risk factors for HL. While our meta-analysis 
provides some support for a variation in XPG/ERCC5 as a risk factors for HL, as well as 8 
other variants, these data should be interpreted with caution as the identified associations 
are not robust on the basis of multiple testing correction and FPRP. 
Even excluding this, a number of general conclusions can be constructed from the 
published studies. Few of the studies variants have been reported as statistically 
significant in more than one study.  It is generally acknowledged that independent 
replication of study findings is a prerequisite to assess the robustness of findings. In some 
studies, the failure to demonstrate a relationship may simply be a consequence of poor 
power because of sample size. Genome-wide association studies (GWAS) of cancer have 
revealed that the relative risk associated with common variants is, typically between 1.1 
and 1.3(47).  Fewer than 40% of the studies we reviewed had 80% power to demonstrate 
even a 2-fold difference in risk at the 0.05 significance level. To overcome this lack of 
power, we have undertaken a meta-analysis pooling the data from the published studies. 
There are, however, caveats to this statistical procedure.  
In any systematic review, publication bias is clearly of great concern. The most common 
scenario is that negative findings may go unreported. Furthermore, many studies excluded 
do not describe the ethnicity of cases or controls, and it is assumed that each 
polymorphism is functional with respect to risk in each study population.  If, however, the 
polymorphism is a neutral marker for another variant, the assumption may well not apply, 
since LD is often population-dependent. Here we have relied on data extractable from 
published reports. Ideally, access to primary data is desirable; in the absence of this it 
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would be advisable that in the future at least summary data be published to allow meta-
analysis to be conducted. 
An important lesson from the published studies is that greater attention should be paid to 
study design.  Data from GWAS have demonstrated a differing allelic architecture of 
genetic susceptibility to HL with respect to histology and EBV status.  Few studies have 
stratified genotype data according to histology and EBV status. This may explain the lack 
of consistency in candidate gene association studies and in our meta-analysis.  Due to the 
lack of stratification in the majority of studies we were unable to include this in our meta-
analysis.  The issue of population stratification in case-control studies and resulting false 
positive results is also of concern. Such associations occur because of population 
subdivision and non-random mating, leading to variation in the marker frequency within the 
population as a result of founder effects and/or genetic drift. The severity of spurious 
association becomes an increasing problem with increasing study size. To avoid this 
problem, potential confounding effect of population stratification should be allowed for in 
the design and analysis of the study. This requires the identification of sub-populations in 
terms of factors that can influence both disease and marker allele frequencies. Provided 
cases and controls are well matched, differences in the frequency of genotypes will only 
be seen at predisposition loci. Hence, stratification can be detected by typing a series of 
unlinked markers chosen from a panel known to exhibit differences in allele frequency 
between populations.   
We have attempted to review published analyses of the relationship between polymorphic 
variation and risk of HL through several iterations of search criteria; it is possible, however, 
that we have missed some published studies.   As the number of articles on genetic 
variation on risk of HL published in the past decade has increased considerably and 
continues to grow, we accept that this review provides a snapshot of progress to date in 
the field.   
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All of the studies we have reviewed have been based on a candidate gene approach. It is 
clear from studies of cancer that without a clear understanding of tumour causalities the 
definition of what constitutes a candidate gene is inherently problematic, making an 
unbiased approach through GWAS highly desirable. Moreover, the possibility of missing 
the identification of important variants in hitherto unstudied genes is avoided. Thus far 
GWAS of HL have provided evidence that variation in a number of genes including REL, 
EOMES, ERAP1, IL13, PVT1, GATA3 and TCF3 (7, 8, 48, 49) influence the risk of 
developing HL.  In contrast to the candidate gene studies, the substantial evidence 
supporting these variants, including sizeable power and replication in large samples, 
indicate that the associations are highly robust. These data thus provide the first 
unambiguous evidence that common low penetrance susceptibility alleles contribute to the 
risk of HL. 
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CONCLUSIONS 
 
The search for polymorphic variants influencing the risk of HL is a worthy enterprise.  
However, the studies that have been conducted to date have important lessons for the 
design and execution of future studies. Candidate gene analyses should be viewed as 
complementary to GWAS, as they theoretically offer advantages both in terms of statistical 
power and an ability to identify low frequency risk variants. Furthermore, many functional 
variants, such as the small scale insertion and deletions in carcinogen metabolism genes, 
are poorly captured by tagging SNPs used in GWAS. It is however, clear that in addition to 
conducting studies using adequate sample, attention should be paid to study design to 
avoid problems of aetiological heterogeneity, population stratification and other sources of 
potential bias in order to maximise the output of any future candidate gene study. 
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Table 1.  Polymorphisms studied as risk factors for Hodgkin Lymphoma. 
Class/Gene Polymorphism Type AA change  Effect Methods of detection 
Immune response 
TNFα rs1800629 A>G 
rs1800750 G>A 
Upstream 
Upstream 
None 
None 
Reduced expression 
Reduced expression 
Taqman 
Taqman 
FCGR2 rs1801274 C>T Missense A519C, 
R131H 
Altered activity Pyrosequencing 
IL1A rs1800587 C>T Upstream None Increased expression Taqman 
IL1B rs16944 G>A Upstream None Altered expression Taqman 
IL4 rs2243248 T>G 
rs2243250C>T 
Upstream 
Upstream 
None 
None 
Altered expression 
Altered expression 
Cycling temperature denaturing electrophoresis 
Sequenom MassARRAY iPLEX 
IL4A rs1801275 A>G Missense Q551R Altered activity Sequenom MassARRAY iPLEX 
IL6  rs1800795 G>C Upstream None Reduced expression Taqman 
IL10 
 
rs1800890: T>A 
rs1800896 G>A 
Upstream 
Upstream 
None 
None 
Lower expression? 
Lower expression> 
Cycling temperature denaturing electrophoresis, PCR 
RFLP Taqman, SSCP 
IL10RA rs2229113: A>G 
rs3135932 A>G 
Missense 
Missense 
G330R 
S159G 
Altered activity 
Altered activity 
PCR-RFLP 
PCR-RFLP 
IRF4A rs872071 A>G Upstream None Altered expression Allele-Specific PCR 
LTC4S rs730012 A>C Upstream None Altered expression Taqman 
CXCL12 rs1801157 G>A Upstream None Altered expression PCR-RFLP 
TLR1 rs5743551 A>G Upstream None Increased expression PCR-RFLP 
TLR2 rs4696480 T>A Upstream None Altered expression PCR-RFLP 
TLR9 rs187084 T>C 
rs5743836 T>C 
Upstream 
Upstream 
None 
None 
Altered expression 
Altered expression 
PCR-RFLP 
PCR-RFLP 
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Carcinogen metabolism 
     
GSTM1 Deletion NA NA Abolishes activity  PCR-RFLP 
GSTT1 Deletion NA NA Abolishes activity PCR-RFLP 
GSTP1 rs1695 A>G Missense I105V Decreased activity Cycling temperature denaturing electrophoresis, PCR-
RFLP 
GSTA1 rs3957357 C>T  Upstream None Altered expression Cycling temperature denaturing electrophoresis 
EPHX rs1051740 T>C Missense T113C Altered activity PCR-RFLP 
 rs2234922 A>G Missense H139G Altered activity PCR-RFLP 
CYP2C9 rs1057910 A>C 
rs1799853 C>T 
Missense 
Missense 
I359L  
R144C 
Altered activity 
Altered activity 
Taqman 
Taqman 
DNA repair 
     
XPA rs1800975 G>A Missense A23G Altered activity Taqman 
XPC rs2228000 A>G 
rs2228001 A>G 
Missense 
Missense 
A499V 
K940Q 
Altered activity 
Altered activity 
Sequenom MassARRAY IPLEX 
Taqman 
XPF/ERCC1 rs3212986 C>A Missense Q504K Altered activity Taqman 
XPG/ERCC5 rs17655 G>C Missense D1104H Altered activity Taqman 
XRCC1 rs1799782 C>T Missense R194W Altered activity Sequenom MassARRAY iPLEX 
XRCC3 rs861539 C>T Missense T241M Altered activity Taqman 
Folate Metabolism 
     
MTHFR 
MTR 
rs1801133 C>T 
rs1805087 A>G 
Missense 
Missense 
A222V 
D919G 
Decreased activity 
Reduced activity 
Taqman, Melting curve analysis, PCR-RFLP 
Taqman 
Others      
COX2 rs5277 C>G 
rs20417 G>C 
rs689466 G>A 
Missense 
Upstream 
Upstream 
G102C 
None 
None 
Altered activity 
Decreased activity 
Decreased activity 
Taqman 
Sequenom MassARRAY iPLEX, Taqman, 
Pyrosequencing 
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ABCC2 rs17222723 T>A Missense V1188E Altered activity Cycling temperature denaturing electrophoresis 
NBN rs1801282 C>A Missense P12A Altered activity Sequenom MassARRAY iPLEX 
TP53 rs1042522     
NFKB1 rs3774937     
NFKB1A rs696 
rs8904 
rs1050851 
rs19571006 
    
CHUK rs2230804     
PTGES rs10448290 
rs2241270 
rs4837404 
    
HPSE rs4693608 
rs11099592 
rs436425 
    
UGT1A1 NA Tandem 
Repeats 
None Reduced promoter 
activity 
PCR-RFLP, Sanger sequencing 
AA, amino acid; NA, not applicable; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism;  
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Table 2.  Studies of polymorphisms and risk of Hodgkin lymphoma. 
Reference Place of study Gene studied Ethnicity N Cases N Controls 
Ruiz-Cosano J et 
al, 2013 
Spain XPG.ERCC5 
MTR 
Caucasian 20 HL a subset of lymphoma cases: 
no other information 
 
214 Healthy blood donors matched for age, 
gender, ethnicity and geographical location 
Yri O et al, 2012 Norway IL10 
GSTP1 
GSTT1 
GSTM1 
UGT1A1 
Unspecified 224 HL patients: 135 males, 89 males: 
mean age 38 (18-84). 
1056 Healthy blood donors (age and gender 
unknown) 
Ruiz-Cosano J et 
al, 2012 
Spain GSTT1 
GSTM1 
Caucasian 20 HL a subset of lymphoma: no 
other information 
 
214 Healthy blood donors matched for age, 
gender, ethnicity and geographical location  
Monroy C et al, 
2011 
USA COX2 Mixed 200 HL patients: mean age 47.2 years 
(SD 13.37 years).  107 males and 
93 females.  80% NSHL. 
220 Frequency matched to the age (within 5 
years), sex, and race/ethnicity of the cases.  
Controls randomly selected random digit 
dialling.  Mean age 49.27 years (SD 15.19 
years).  123 males and 97 females. 
Kasperzyk J et al, 
2010 
USA MTHFR 
MTR 
Mixed 
(predominantly 
Caucasian) 
497 HL patients: mean age 38 years 
(SD 15 years).   EBV positive 
16.3% and EBV negative 57.6%.  
NLPHL excluded from the study. 
638 Frequency matched to the age (within 5 
year age groups), sex, and state of 
residency distribution of the cases.  
Controls randomly selected through “town 
books” in Boston or random digit dialling in 
Connecticut. 
Ribrag V et al, 
2009 
France GSTT1 
GSTM1 
GSTP1 
UGT1A1 
Unspecified 313 HL patients: 180 males, 133 
females.  Median age 32 years 
(range 15-93 years). 
226 Controls obtained from the French Blood 
Service. 
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Lourenco G et al, 
2009 
Brazil GSTP1 
GSTT1 
GSTM1 
 
Mixed 110 HL patients: median age 27 years 
(range 14-82 years), 57 males 53 
females.  Genotype data stratified 
by age, gender, ethnic origin and 
stage of disease. 
226 Blood donors: median age 52 years (range 
25-60 years), 151 males, 75 females. 
 
El-Zein R et al, 
2009 
 
USA 
 
XPG/ERCC5 
 
Mixed 
 
200 
 
HL patients: mean age 47.2 years 
(SD 13.37 years).  107 males and 
93 females. 
 
220 
 
Frequency matched to the age (within 5 
years), sex, and race/ethnicity of the cases.  
Controls randomly selected random digit 
dialling.  Mean age 49.27 years (SD 15.19 
years).  123 males and 97 females. 
 
Chang E et al, 
2009 
USA COX2 Mixed 473 HL patients: 242 males, 231 
females.  NLPHL excluded from 
the study. 
373 Frequency matched to the age (within 5 
year age groups), sex, and state of 
residency distribution of the cases.  
Controls in Boston randomly selected 
through “town books”.  Controls in 
Connecticut randomly selected through 
digit dialling (18-65 years of age) or 
Medicare files (66-79 years of age).  211 
males and 162 females. 
 
 
Hoeft K et al, 
2008 
 
Germany 
 
COX2 
Unspecified  
116 
 
HL a subset of lymphoma cases. 
 
710 
 
Randomly selected from the population 
registers of the study region.  Matched for 
gender, age (1 year) and study region.  390 
males and 320 females. 
Timuragaoglu A et 
al, 
2006 
Turkey MTHFR 
 
Unspecified 30 
 
HL a subset of lymphoma cases. 
82 Frequency matched to cases by age and 
gender. 
Deligezer A et al, 
2006 
Turkey MTHFR 
 
Unspecified 51 
 
HL a subset of lymphoma cases.  
22 cases MCHL, 20 NSHL, 9 
LRHL.  Median age 35 years 
(range 19-70), 35 males, 31 
females. 
154 Frequency matched to cases by age and 
gender of similar ethnic background.  
Randomly selected. 
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Nieters A et al, 
2006 
Germany IL10 Unspecified 115 
 
HL a subset of lymphoma cases. 
710 1:1 matched for gender, age (within 1 year) 
and study region. 
Cordano et al, 
1999 
UK IL6 Unspecified 584 HL patients: 61.3% NSHL and 
21.4% cHL.  33% EBV positive. 
513 Frequency matched to cases by age and 
gender, region of residence. 
Cozen W et al, 
2004 
USA IL6 Mixed 
(predominantly 
Caucasian) 
27 HL patients: an affected twin of a 
monozygotic or dizygotic pair.  
Geneotype data stratified by 
zygosity and histology. 
201 Spouses within 5 years of the twins’ ages, 
non-blood relative/friend or a age (within 5 
years) or ethnicity-matched control subject 
was chosen from employees within the 
institution. 
Munro L et al, 
2003 
UK IL10 Unspecified 125 HL patients: mean age 44.04 
years, 52.7% NSHL, 17.7 MCHL, 
6.8% NLPHL, 2% LRCHL, 19. UC.  
69 males, 88 females.  Geneotype 
data stratified by histopathology. 
125 Mean age 58.3 years, 51 males, 60 
females. 
Hohaus S et al, 
2003 
Italy GSTT1 
GSTM1 
Unspecified 90 HL patients: median age 33 years, 
54 males, 36 females.  67 NSHL, 
7 MCHL, 6 NLPHL, 1 LDHL, 9 
UC.  Geneotype data stratified by 
age and gender. 
176 Matched for sex and age (69 females, 107 
males; median age 38 years, range 19–71 
years) 
Cunningham L et 
al, 2003 
Australia IL10 Mixed 44 
 
HL a subset of lymphoma cases. 
164 Geographically and ethnically similar 
metropolitan population. 
Sarmanova J et 
al, 2001 
Norway GSTP1 
GSTT1 
Caucasian 143 
 
HL a subset of lymphoma cases.  
Genotype data stratified by 
gender. 
455 Similar gender and age distribution as 
overall lymphoma cohort.  Staff from 
institute and nearby inhabitants of houses 
for elderly citizens. 
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GSTM1 
 
Gonzalez 
Ordonez A et al, 
2000 
Spain MTHFR 
 
Unspecified 29 
 
HL a subset of lymphoma cases.  
Mean age 24 years (SD 15 years). 
 
200 Healthy Spanish volunteers. 
Lemos M et al, 
1999 
Portugal GSTM1 
 
Portuguese 25 
 
HL a subset of lymphoma cases. 
128 Unrelated Portuguese Caucasian 
volunteers; 56 males, 72 females; no 
history of cancer or other chronic disease; 
no age-matching. 
HL, Hodgkin Lymphoma; SD, standard deviation; EBV, Epstein-Barr Virus; cHL, Classical Hodgkin Lymphoma; NSHL, nodular sclerosis Hodgkin Lymphoma; MCHL, mixed 
cellularity Hodgkin Lymphoma; LRHL, lymphocyte-rich Hodgkin-Lymphoma; LDHL, lymphocyte-depleted Hodgkin-Lymphoma; NLPHL, nodular lymphocyte-predominant 
Hodgkin-Lymphoma; UC, unclassified 
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Table 3.  Summary of odds ratios of individual studies along with their confidence intervals. 
  Heterozygous model  Homozygous model  Carrier status 
   95% CIs    95% CIs    95% CIs  
Study Polymorphism OR Upper Lower P  OR Upper  Lower P  OR Upper Lower P 
Yri IL-10, rs1800890 0.95 1.30 0.69 0.74  1.41 2.17 0.94 0.12  1.04 1.40 0.77 0.80 
Nieters IL-10, rs1800890 1.07 1.63 0.7 0.77  0.63 1.29 0.19 0.20  0.96 1.45 0.64 0.86 
Nieters IL10, rs1800896 0.96 1.51 0.61 0.86  0.62 1.14 0.15 0.12  0.85 1.30 0.55 0.45 
Munro IL10, rs1800896 0.84 1.48 0.47 0.54  0.83 1.68 0.44 0.61  0.84 1.43 0.49 0.51 
Cunningham IL10, rs1800896 0.92 2.00 0.43 0.84  0.54 1.49 0.18 0.23  0.79 1.66 0.38 0.54 
Cordano IL6, rs1800795 0.85 1.17 0.61 0.32  1.03 1.58 0.19 0.88  0.89 1.21 0.66 0.47 
Cozen IL6, rs1800795 0.58 1.13 0.30 0.11  0.35 0.95 0.14 0.04  0.52 0.98 0.27 0.04 
Yri GSTP1, rs1695 0.85 1.17 0.62 0.32  1.33 2.03 0.24 0.19  0.96 1.28 0.71 0.76 
Lourenco GSTP1, rs1695 0.34 0.57 0.20 0.00  0.58 1.13 0.04 0.11  0.39 0.63 0.25 0.00 
Ribrag GSTP1, rs1695 1.01 1.49 0.68 0.97  1.06 1.90 0.66 0.85  1.02 1.47 0.71 0.92 
Sarmanova GSTP1, rs1695 0.77 1.33 0.44 0.35  1.88 3.70 0.38 0.06  1.00 1.61 0.61 0.98 
Yri GSTT1, deletion NA NA NA NA  NA NA NA NA  3.17 5.09 1.97 0.00 
Ruiz-Cosano GSTT1, deletion NA NA NA NA  NA NA NA NA  2.95 7.96 1.10 0.03 
Ribrag GSTT1, deletion NA NA NA NA  NA NA NA NA  0.90 1.47 0.55 0.67 
Lourenco GSTT1, deletion NA NA NA NA  NA NA NA NA  0.92 1.65 0.51 0.78 
Hohaus GSTT1, deletion NA NA NA NA  NA NA NA NA  1.90 3.46 1.04 0.03 
Sarmanova GSTT1, deletion NA NA NA NA  NA NA NA NA  0.88 1.79 0.43 0.72 
Yri GSTM1, deletion NA NA NA NA  NA NA NA NA  1.18 1.57 0.88 0.27 
Ruiz-Cosano GSTM1, deletion NA NA NA NA  NA NA NA NA  0.53 1.34 0.21 0.18 
Ribrag GSTM1, deletion NA NA NA NA  NA NA NA NA  0.83 1.2 0.58 0.33 
Lourenco GSTM1, deletion NA NA NA NA  NA NA NA NA  1.35 2.14 0.86 0.19 
Hohaus GSTM1, deletion NA NA NA NA  NA NA NA NA  0.75 1.25 0.45 0.26 
Sarmanova GSTM1, deletion NA NA NA NA  NA NA NA NA  0.90 1.45 0.55 0.66 
Lemos GSTM1, deletion NA NA NA NA  NA NA NA NA  0.93 2.20 0.39 0.87 
Ruiz-Cosano XPG/ERCC5, rs17655 1.89 5.28 0.68 0.22  4.86 18.69 3.81 0.01  2.33 6.06 0.89 0.08 
El-Zein XPG/ERCC5, rs17655 1.19 1.79 0.79 0.40  1.63 3.60 0.58 0.22  1.25 1.84 0.85 0.26 
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Kasperzyk MTHFR, rs1801133 0.76 1.03 0.56 0.08  0.96 1.52 0.16 0.87  0.80 1.06 0.60 0.13 
Timuragaoglu MTHFR, rs1801133 1.15 2.77 0.48 0.75  0.55 2.87 0.42 0.48  1.02 2.38 0.44 0.96 
Deligezer MTHFR, rs1801133 0.49 0.96 0.25 0.04  0.26 1.19 0.07 0.06  0.45 0.85 0.23 0.01 
Gonzales Ordonez MTHFR, rs1801133 0.77 1.76 0.33 0.53  0.92 3.48 0.34 0.9  0.8 1.73 0.36 0.56 
Ruiz-Cosano MTR, rs1805087 0.84 2.70 0.26 0.78  5.81 21.90 2.06 0.00  1.47 3.73 0.58 0.41 
Kasperzyk MTR, rs1805087 0.93 1.26 0.68 0.65  0.60 1.22 0.16 0.16  0.88 1.18 0.66 0.41 
Monroy COX2, rs20417 1.39 0.74 2.6 0.31  6.94 2.68 59.16 0.04  1.6 2.93 0.87 0.13 
Chang COX2, rs20417 1.11 1.49 0.82 0.51  1.99 4.24 0.65 0.07  1.18 1.57 0.88 0.27 
Hoeft COX2, rs20417 1.05    1.65 0.67 0.83  NA NA NA NA  0.99 1.55 0.63 0.97 
Chang COX2, rs689466 0.99 1.36 0.73 0.97  1.16 2.39 0.33 0.69  1.01 1.36 0.75 0.93 
Hoeft COX2, rs689466 0.99 1.53 0.63 0.95  0.31 2.35 0.31 0.23  0.93 1.43 0.60 0.73 
Yri UGT1A1, tandem repeat 0.90 1.22 0.66 0.49  0.79 1.32 0.16 0.37  0.88 1.17 0.66 0.37 
Ribrag UGT1A1, tandem repeat 0.70 1.04 0.47 0.07  0.71 1.32 0.12 0.28  0.70 1.02 0.48 0.06 
CI, confidence interval; OR, odds ratio 
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Table 4.  Pooled odds ratios of all polymorphisms examined more than once in the literature including data from GWAS 
together with the false positive report probabilities (FPRP). 
 Power 
 
FPRP at prior probability 
of 0.001 
Gene, variant Studies Cases Controls OR P Phet I
2
 OR=1.2 OR=1.5 OR=1.2 OR=1.5 
IL-10 rs1800890 2 334 1709         
AT vs TT    0.99 (0.77 - 1.28) 0.93 0.67 0 0.91 1.00   
AA vs TT     0.99 (0.45 - 2.18) 0.98 0.06 72% 0.67 0.84   
Carrier    1.01 (0.79 - 1.29) 0.93 0.77 0 0.92 1.00   
IL10, rs1800896 5 1573 7026         
AG vs AA    1.01 (0.84 – 1.20) 0.95 0.89 0 0.98 1.00   
GG vs AA    0.88 (0.50 – 1.54) 0.65 0.01 73% 0.58 0.84   
Carrier    1.06 (0.89 – 1.25) 0.53 0.34 10% 1.00 1.00   
IL-6 rs1800795 2 435 374         
GC vs GG    0.79 (0.59 - 1.06) 0.11 0.316 1% 0.53 0.93   
CC vs GG    0.86 (0.59 - 1.29) 0.50 0.05 74% 0.78 0.97   
Carrier    0.92 (0.32 – 2.63) 0.17 <0.01 88.5% 0.63 0.96   
GSTP1, rs1695 6 2185 8287         
AG vs GG    0.82 (0.63 – 1.07) 0.15 <0.001 79% 0.45 0.94   
AA vs GG    1.08 (0.92 – 1.27) 0.35 0.06 52% 0.90 1.00   
Carrier    0.88 (0.69 – 1.13) 0.32 <0.001 78% 0.67 0.99   
GSTT1 deletion 6 796 2058         
Carrier    1.50 (0.90 - 2.50) 0.12 0 76% 0.20 0.50   
GSTM1 deletion 7 835 2205         
Carrier    0.99 (0.84-1.17) 0.90 0.32 15% 0.98 1   
XPG/ERCC5, rs17655 3 1094 1651         
GC vs GG    0.94 (0.80 – 1.12) 0.50 0.17 44% 0.91 1.00   
CC vs GG    1.68 (1.18 – 2.37) 0.01 0.27 23% 0.03 0.26 0.99 0.99 
Carrier    1.01 (0.86 – 1.19) 0.88 0.10 57% 0.65 0.82   
MTHFR rs1801133 4 2025 7202         
CT vs CC    0.96 (0.85 – 1.07) 0.47 0.19 33% 0.99 1.00   
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TT vs CC    0.98 (0.82 – 1.17) 0.80 0.62 0 0.97 1.00   
Carrier    0.96 (0.86 – 1.07) 0.45 0.15 38% 1.00 1.00   
MTR rs1805087 4 1936 6991         
AG vs AA    0.97 (0.86 – 1.10) 0.63 0.99 0 0.99 1.00   
GG vs AA    1.18 (0.88 – 1.57) 0.27 0.05 67% 0.55 0.95   
Carrier    0.99 (0.88 – 1.11) 0.86 0.72 0 0.99 1.00   
COX2 rs20417 4 1538 2333         
GC vs GG    1.01 (0.92 – 1.24) 0.41 0.83 0 0.95 1.00   
CC vs GG    1.37 (0.88 – 2.13) 0.17 0.16 43% 0.28 0.67   
Carrier    1.01 (0.94 – 1.26) 0.27 0.50 0 0.94 1.00   
COX2 rs689466 2 567 1024         
AG vs AA    0.991 (0.77 - 1.28) 0.94 0.98 0 0.91 1   
GG vs AA    0.92 (0.48 - 1.76) 0.81 0.22 33% 0.62 0.84   
Carrier    0.98 (0.77 - 1.26) 0.90 0.74 0 0.91 1   
UGT1A1 TR 2 532 1208         
6/7 vs 6/6    0.82 (0.64 - 1.040) 0.10 0.33 0 0.44 0.95   
7/7 vs 6/6    0.76 (0.51 - 1.13) 0.17 0.79 0 0.32 0.74   
Carrier    0.81 (0.64 - 1.01) 0.06 0.36 0 0.38 0.95   
CI, confidence interval; OR, odds ratio 
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Table 5.  Pooled odds ratios of all the polymorphisms examined once in the literature and GWAS data with the false positive 
report probabilities (FPRP). 
 
 Power 
 
FPRP at prior probability 
of 0.001 
Gene, variant Studies Cases Controls OR P Phet I
2
 OR=1.2 OR=1.5 OR=1.2 OR=1.5 
TNF, rs1800750 2 928 1345         
GA vs GG    1.78 (0.34 – 9.19) 0.50 0.01 84% 0.32 0.42   
AA vs GG            
Carrier    1.78 (0.34 – 9.19) 0.50 0.01 84% 0.32 0.42   
TNF, rs1800629 2 987 1893         
GA vs GG    1.14 (0.94 – 1.37) 0.19 0.66 0 0.71 1.00   
AA vs GG    1.17 (0.74 – 1.87) 0.50 0.43 0 0.54 0.85   
Carrier    1.14 (0.95 – 1.37) 0.15 0.81 0 0.71 1.00   
FCGR2, rs1801274 3 1704 7938         
CT vs CC    1.15 (1.00 - 1.31) 0.05 0.93 0 0.74 1.00   
TT vs CC    1.07 (0.91 - 1.26) 0.40 0.37 0 0.92 1.00   
Carrier    1.12 (0.99 - 1.27) 0.08 0.96 0 0.86 1.00   
IL1A, rs1800587 2 977 1877         
CT vs CC    0.85 (0.72 – 1.00) 0.05 0.87 0 0.59 1.00   
TT vs CC    0.72 (0.54 – 0.96) 0.02 0.10 63% 0.70 0.99 1.00 1.00 
Carrier    1.00 (0.60 – 1.67) 0.99 0.03 80% 0.94 1.00   
IL1B, rs16944 2 981 1876         
GA cs GG    1.03 (0.87 – 1.22) 0.73 0.17 47% 0.96 1.00   
AA vs GG    1.36 (1.05 – 1.77) 0.02 0.329 9% 0.18 0.77 0.99 0.97 
Carrier    1.09 (0.93 – 1.28) 0.30 0.41 0 0.88 1.00   
IL-4 rs2243248 3 1685 7465         
TG vs GG    0.97 (0.70 - 1.33) 0.83 0.04 70% 0.83 0.99   
GG vs TT    0.88 (0.42 - 1.86) 0.50 0.44 0 1.00 1.00   
Carrier    1.02 (0.86 – 1.20) 0.84 0.08 61% 0.98 1.00   
IL-4 rs2243250 2 976 1318         
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CT vs CC    1.06 (0.87 - 1.28) 0.58 0.91 0 0.90 1.00   
TT vs CC     1.17 (0.69 – 2.00) 0.57 0.08 68% 0.54 0.82   
Carrier    1.29 (0.77 – 2.16) 0.33 0.05 75% 0.39 0.72   
IL4A rs1801275 3 1565 6517         
AG vs AA    0.87 (0.76 – 0.99) 0.03 0.0 0 0.74 1.00 0.98 0.97 
GG vs AA    1.07 (0.80 -1.43) 0.65 0.29 18% 0.78 0.99   
carrier    0.89 (0.79 – 1.01) 0.07 0.70 0 0.85 1.00   
IL10, rs1800872 2 987 1893         
CA vs CC    0.98 (0.82 – 1.16) 0.79 0.09 64% 0.97 1.00   
AA vs CC    1.26 (0.82 – 1.93) 0.30 0.65 0 0.41 0.79   
Carrier    1.00 (0.85 – 1.20) 0.96 0.16 49% 0.98 1..00   
IL10RA, rs2229113 3 986 1890         
CT vs CC    0.85 (0.72 – 1.01) 0.06 0.97 0 0.59 1.00   
TT vs CC    0.81 (0.62 – 1.06) 0.12 0.88 0 0.40 0.96   
Carrier    0.84 (0.72 – 0.99) 0.04 0.93 0 0.54 1.00 0.97 0.97 
IL10RA, rs3135932 3 987 1893         
AG vs AA    0.98 (0.82 – 1.16) 0.76 0.09 64% 0.97 1.00   
GG vs AA    1.26 (0.82 – 1.93) 0.30 0.65 0 0.41 0.79   
Carrier    1.26 (0.46 – 3.48) 0.65 <0.001 94% 0.46 0.63   
IRF4, rs872071 3 1592 7442         
AG vs GG    0.92 (0.81 – 1.04) 0.19 0.41 0 0.94 1.00   
AA vs GG    0.88 (0.76 – 1.02) 0.09 0.39 0 0.77 1.00   
Carrier    0.90 (0.80 – 1.02) 0.09 0.52 0 0.89 1.00   
LTC4S, rs730012 3 1915 6778         
CA vs AA    0.94 (0.84 – 1.06) 0.34 0.41 0 0.98 1.00   
CC vs AA    0.97 (0.79 – 1.19) 0.75 0.44 0 0.93 1.00   
CArrier    0.95 (0.85 – 1.06) 0.35 0.44 0 0.99 1.00   
CXCL12, rs1801157 2 912 1308         
GA vs GG    1.05 (0.87 – 1.23) 0.60 0.97 0 0.95 1.00   
AA vs GG    1.26 (0.78 – 2.02) 0.34 0.43 0 0.42 0.77   
Carrier    1.07 (0.89 – 1.28) 0.46 0.75 0 0.90 1.00   
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TLR1, rs5743551 2 985 1881         
AG vs AA    0.90 (0.76 – 1.06) 0.21 0.12 59% 0.82 1.00   
GG vs AA    1.02 (0.72 – 1.45) 0.91 0.95 0 0.82 0.98   
Carrier    0.91 (0.77 – 1.07) 0.27 0.16 50% 0.57 0.74   
TLR2, rs4696480 2 986 1982         
TA vs TT    1.47 ( 0.89 – 2.45) 0.13 0.05 75% 0.22 0.53   
AA vs TT    1.09 (0.86 – 1.37) 0.48 0.20 40% 0.80 1.00   
Carrier    1.42 (0.85 – 2.37) 0.18 0.04 76% 0.26 0.59   
TLR9, rs187084 2 986 1982         
TC vs TT    0.97 (0.81 – 1.16) 0.71 0.63 0 0.95 1.00   
CC vs TT    0.83 (0.65 – 1.04) 0.11 0.99 0 0.49 0.97   
Carrier    0.93 (0.78 – 1.10) 0.72 0.34 0 0.90 1.00   
TLR9, rs5743836 2 986 1982         
TC vs TT    1.11 (0.91 – 1.34) 0.31 0.08 68% 0.79 1.00   
CC vs TT    1.02 (0.80 – 1.30) 0.89 0.99 0% 0.91 0.99   
Carrier    1.07 (0.89 – 1.23) 0.50 0.12 59% 0.95 1.00   
GSTA1, rs3957357 3 1688 7403         
CT vs CC    1.07 (0.91 – 1.25) 0.41 0.19 40% 0.93 1.00   
TT vsCC    0.81 (0.55 – 1.19) 0.28 0.67 0 0.44 0.84   
Carrier    1.04 (0.89 – 1.21) 0.62 0.23 33% 0.97 1.00   
EPHX, rs1051740 2 953 1665         
TC vs TT    0.98 (0.83 – 1.17) 0.83 0.28 14% 0.96 1.00   
CC vs TT    2.76 (0.20 – 38.40) 0.45 <0.001 97% 0.27 0.33   
Carrier    1.14 (0.97 – 1.35) 0.11 0.06 72% 0.72 1.00   
EPHX, rs2234922 2 666 5652         
AG vs AA    0.87 (0.73 – 1.03) 0.11 0.78 0 0.70 1.00   
GG vs AA    0.93 (0.61 – 1.42) 0.73 0.34 0 0.70 0.94   
Carrier    0.87 (0.73 – 1.03) 0.11 0.58 0     
CYP2C9, rs1057910 2 1054 5570         
AC vs AA    1.26 (1.02 – 1.54) 0.03 0.97 0 0.70 1.00 0.99 0.96 
CC vs AA    1.33 (0.49 – 3.67) 0.58 0.31 4% 0.42 0.59   
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Carrier    1.30 (1.03 – 1.54) 0.03 0.87 0 0.18 0.95 0.93 0.72 
CYP2C9, rs1799853 2 1059 5569         
CT vs CC    1.28 (1.07 – 1.51) 0.01 0.21 38% 0.22 0.97 0.94 0.78 
TT vs CC    0.34 (0.02 – 6.89) 0.48 0.04 75% 0.28 0.33   
Carrier    1.24 (1.05 – 1.46) 0.01 0.41 0 0.35 0.99 1.00 0.99 
XPA, rs1800975 2 896 1432         
GA vs GG    0.92 (0.76 – 1.10) 0.37 0.13 57% 0.86 1.00   
AA vs GG    3.60 (0.49 – 26.70) 0.21 0.01 86% 0.14 0.20   
Carrier    1.02 (0.86 – 1.22) 0.25 0.06 72% 0.96 1.00   
XPC, rs2228000 2 984 1878         
GA vs GG    0.84 (0.71 – 1.00) 0.05 0.53 0 0.52 0.89   
AA vs GG    0.89 (0.70 – 1.50) 0.47 0.14 46% 0.60 0.86   
Carrier    0.85 (0.71 – 1.00) 0.05 0.99 0 0.59 1.00   
XPC, rs2228001 2 1663 6637         
GT vs TT    0.98 (0.86 – 1.12) 0.78 0.97 0 0.99 1.2   
GG vs TT    1.01 (0.85 – 1.20) 0.93 0.33 10% 0.98 1.00   
Carrier    0.99 (0.86 – 1.12) 0.84 0.88 0 0.91 1.00   
ERCC1, rs3212986 3 1633 6715         
CA vs CC    0.80 (0.69 – 0.91) 0.001 0.85 0 0.27 1.00 0.72 0.41 
AA vs CC    0.87 (0.68 – 1.22) 0.28 0.22 35% 0.60 0.94   
Carrier    0.81 (0.72 – 0.91) 0.001 0.98 0 0.32 1.00 0.56 0.28 
XRCC1, rs1799782 2 1072 1436         
CT vs CC    0.69 (0.28 – 1.71) 0.42 0.01 84% 0.35 0.53   
TT vs CC    0.73 (0.26 – 2.10) 0.56 0.38 0 0.40 0.57   
Carrier    0.66 (0.25 – 1.74) 0.42 0.01 86% 0.32 0.50   
XRCC3, rs861539 3 912 1308         
GA vs GG    0.97 (0.86 – 1.10) 0.68 0.30 17% 0.99 1.00   
AA vs GG    1.05 (0.88 – 1.26) 0.57 0.74 0 0.92 1.00   
Carrier    0.99 (0.88 – 1.12) 0.89 0.34 7% 1.00 1.00   
COX2 rs5277 2 1334 1577         
CG vs CC    1.07 (0.90 – 1.27) 0.45 0.36 0 0.91 1.00   
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GG vs CC    0.79 (0.50 – 1.25) 0.31 0.73 0 0.41 0.77   
Carrier    1.01 (0.86 – 1.19) 0.92 0.69 0 0.98 1.00   
ABCC2, rs17222723 3 1688 6517         
AT vs TT    0.97 (0.79 – 1.20) 0.80 0.74 0 0.92 1.00   
AA vs TT    2.02 (0.85 – 4.77) 0.11 0.19 40% 0.12 0.25   
Carrier    1.01 (0.83 – 1.23) 0.94 0.95 0 0.96 1.00   
NBN, rs1801282 2 1044 1435         
CA vs CC    1.07 (0.89 – 1.29) 0.45 0.06 70% 0.95 1.00   
AA cs CC    0.99 (0.61 – 1.60) 0.95 0.21 37% 0.76 0.75   
Carrier    1.07 (0.89 – 1.27) 0.50 0.19 42% 0.71 0.95   
TP53, rs104522 2 1174 1967         
GC vs CC    1.12 (0.96 – 1.30) 0.16 0.65 0 0.81 1.00   
GG vs CC    0.96 (0.71 – 1.29) 0.76 0.54 0 0.83 0.99   
Carrier    1.09 (0.94 – 1.26) 0.25 0.57 0     
NFKB1, rs3774937 2 1041 5565         
TC vs TT    1.02 (0.86 – 1.18) 0.92 0.65 0 0.90 1.00   
CC vs TT    1.13 (0.90 – 1.44) 0.29 0.46 0 0.69 0.99   
Carrier    0.85 (0.56 – 1.30) 0.45 0.01 86% 0.54 0.87   
NFKB1A, rs696 2 1052 5563         
AG vs GG    1.24 (1.06 – 1.45) 0.01 0.56 0 0.34 0.99 0.95 0.88 
AA vs GG    1.40 (1.12 – 1.74) 0.003 0.25 23% 0.08 0.733 0.97 0.77 
Carrier    1.27 (1.10 – 1.48) 0.002 0.35 0 0.23 0.98 0.90 0.70 
NFKB1A, rs8904 2 1046 5566         
CT cs CC    1.13 (0.96 – 1.32) 0.14 0.20 40% 0.78 1.00   
TT vs CC    1.11 (0.89 – 1.39) 0.36 0.05 75% 0.77 1.00   
Carrier    1.12 (0.97 – 1.31) 0.13 0.08 67% 0.81 1.00   
NFKB1A, rs1050851 2 1331 1579         
CT vs CC    0.87 (0.50 – 1.48) 0.60 0.002 90% 0.56 0.84   
TT vs CC    0.88 (0.61 – 1.28) 0.51 0.52 0 0.61 0.93   
Carrier    0.87 (0.52 – 1.44) 0.58 0.002 89% 0.57 0.85   
NFKB1A, rs19571006            
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AT vs AA    1.09 (0.93 – 1.27) 0.30 0.90 0 0.89 1.00   
TT vs AA    1.29 (0.67 – 2.48) 0.45 0.04 75% 0.41 0.67   
Carrier    1.09 (0.94 – 1.27) 0.24 0.61 0 0.89 1.00   
CHUK, rs2230804 2 1339 1577         
AG vs AA    0.81 (0.54 – 1.24) 0.33 0.03 78% 0.45 0.82   
GG vs AA    0.75 (0.48 – 1.17) 0.21 0.04 75% 0.32 0.70   
Carrier    0.80 (0.52 – 1.22) 0.29 0.02 82% 0.43 0.80   
PTGES, rs10448290 2 986 1884         
AC vs AA    0.99 (0.80 – 1.23) 0.93 0.79 0 0.94 1.00   
CC vs AA    1.42 (0.61 – 3.31) 0.41 0.06 71% 0.35 0.55   
Carrier    1.01 (0.81 – 1.24) 0.96 0.48 0 0.95 1.00   
PTGES, rs2241270 2 700 5866         
AC vs AA    0.99 (0.82 – 1.20) 0.93 0.84 0 0.97 1.00   
CC vs AA    0.90 (0.48 – 1.68) 0.73 0.77 0 0.60 0.83   
Carrier    0.94 (0.82 – 1.18) 0.87 0.79 0 0.85 1.00   
PTGES, rs4837404 2 1326 1579         
AG vs AA    1.10 (0.94 – 1.29) 0.25 0.87 0 0.78 0.99   
GG vs AA    1.08 (0.85 – 1.34) 0.51 0.41 0 0.83 1.00   
Carrier    1.09 (0.94 – 1.27) 0.24 0.92 0 0.89 1.00   
HPSE, rs4693608 3 1481 6520         
GA vs GG    0.98 (0.84 – 1.14) 0.77 0.91 0 0.98 1.00   
AA vs GG    0.98 (0.82 – 1.15) 0.70 0.88 0 0.98 1.00   
Carrier    0.98 (0.85 – 1.13) 0.76 0.86 0 0.99 1.00   
HPSE, rs11099592 3 1483 6520         
GA vs GG    1.09 (0.96 – 1.24) 0.17 0.51 0 0.93 1.00   
AA vs GG    0.87 (0.66 – 1.16) 0.35 0.30 16% 0.62 0.97   
Carrier    1.06 (0.94 – 1.20) 0.34 0.39 0 0.98 1.00   
HPSE, rs436425 2 607 5302         
TC vs TT    1.00 (0.82 – 1.20) 0.97 0.60 0 0.98 1.00   
CC vs TT    0.90 (0.66 – 1.23) 0.51 0.26 21% 0.69 0.97   
Carrier    0.98 (0.83 – 1.16) 0.81 0.94 0 0.97 1.00   
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UGT1A6, rs1105879 3 1929 6774         
TC vs CC    0.96 (0.85 – 1.08) 0.46 0.40 0 0.99 1.00   
CC vs TT    1.02 (0.85 – 1.21) 0.87 0.74 0 0.97 1.00   
Carrier    0.97 (0.87 – 1.09) 0.58 0.60 0 1.00 1.00   
UGT1A6, rs2070959 3 1923 6785         
AG vs AA    0.97 (0.86 – 1.09) 0.61 0.54 0 1.00 1.00   
GG vs AA    1.07 (0.89 – 1.28) 0.49 0.66 0 0.86 1.00   
Carrier    1.77 (0.56 – 5.52) 0.33 <0.001 99% 0.25 0.39   
 
CI, confidence interval; OR, odds ratio
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Figure 1. Inclusion and exclusion criteria for studies 
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Figure 2. Forest plot of odds ratios (ORs) of Hodgkin lymphoma associated with 
polymorphic variant XPG/ERCC5 rs17655 CC versus GG. Boxes denote allelic OR 
point estimates, their areas being proportional to the inverse variance weight of the 
estimate. Horizontal lines represent 95% confidence intervals (CI). The diamond 
(and broken line) represents the summary OR computed under a fixed effects 
model, with 95% CI given by its width. The unbroken vertical line is at the null value 
(OR = 1.0) 
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Figure 3. Begg’s funnel plot (using odds ratio (OR) of Hodgkin lymphoma risk 
associated with variant genotype rs17655 CC versus GG). The horizontal line 
represents the meta-analysis summary estimate, and the diagonal lines pseudo-95% 
CI limits about the effect estimate. In the absence of publication bias, studies will be 
distributed symmetrically above and below the horizontal line. Asymmetry on the 
top of the graph indicates evidence of publication bias towards studies reporting a 
positive logOR. LogOR, natural logarithm of the OR; s.e. of logOR, standard error of 
the logOR 
 
 
 
